Interferon-free antiviral combination therapies without nucleosidic polymerase inhibitors.

Abstract excerpt

The establishment of robust HCV cell culture systems and characterization of the viral life cycle provided the molecular basis for highly innovative, successful years in HCV drug development. With the identification of direct-acting antiviral agents (DAAs), such as NS3/4A protease inhibitors, NS5A replication complex inhibitors, nucleotide and non-nucleoside polymerase inhibitors, as well as host cell targeting...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Drug Therapy, Combination
• Share to Hepatitis C
• Share to Interferons